
Rhythm (RYTM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
48.5M
Gross Profit
43.0M
88.57%
Operating Income
-45.3M
-93.39%
Net Income
-46.6M
-96.14%
EPS (Diluted)
$-0.75
Balance Sheet Metrics
Total Assets
386.7M
Total Liabilities
223.6M
Shareholders Equity
163.1M
Debt to Equity
1.37
Cash Flow Metrics
Operating Cash Flow
-35.4M
Free Cash Flow
-40.4M
Revenue & Profitability Trend
Rhythm Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 130.1M | 77.4M | 23.6M | 3.2M | 0 |
Cost of Goods Sold | 13.4M | 9.3M | 2.1M | 599.0K | 0 |
Gross Profit | 116.8M | 68.1M | 21.5M | 2.6M | 0 |
Gross Margin % | 89.7% | 88.0% | 91.0% | 81.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 238.0M | 135.0M | 108.6M | 104.1M | 90.4M |
Selling, General & Administrative | 144.3M | 117.5M | 92.0M | 68.5M | 46.1M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 382.3M | 252.5M | 200.7M | 172.6M | 136.6M |
Operating Income | -265.5M | -184.4M | -179.2M | -170.1M | -136.6M |
Operating Margin % | -204.0% | -238.1% | -757.9% | -5,391.9% | 0.0% |
Non-Operating Items | |||||
Interest Income | 14.7M | 13.9M | 4.0M | 447.0K | 2.6M |
Interest Expense | 20.6M | 13.9M | 5.2M | 0 | 0 |
Other Non-Operating Income | 11.1M | 190.0K | -790.0K | 100.0M | - |
Pre-tax Income | -260.3M | -184.1M | -181.1M | -69.6M | -134.0M |
Income Tax | 346.0K | 564.0K | 0 | 0 | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -260.6M | -184.7M | -181.1M | -69.6M | -134.0M |
Net Margin % | -200.3% | -238.5% | -766.2% | -2,207.1% | 0.0% |
Key Metrics | |||||
EBITDA | -247.0M | -168.5M | -174.2M | -68.5M | -133.3M |
EPS (Basic) | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 |
EPS (Diluted) | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 |
Basic Shares Outstanding | 60995204 | 57673128 | 52120701 | 49600294 | 44127220 |
Diluted Shares Outstanding | 60995204 | 57673128 | 52120701 | 49600294 | 44127220 |
Income Statement Trend
Rhythm Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 89.1M | 60.1M | 127.7M | 59.2M | 100.9M |
Short-term Investments | 231.4M | 215.8M | 205.6M | 235.6M | 71.9M |
Accounts Receivable | 18.5M | 14.9M | 6.2M | 1.0M | 0 |
Inventory | 18.7M | 8.6M | 2.9M | 111.0K | - |
Other Current Assets | 8.8M | 6.7M | 7.4M | 4.0M | 3.0M |
Total Current Assets | 374.2M | 308.3M | 354.2M | 308.4M | 181.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.5M | 781.0K | 1.2M | 1.5M | 1.8M |
Goodwill | 6.2M | 7.0M | 7.9M | 4.7M | 0 |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 7.8M | 15.3M | 17.0M | 12.1M | 403.0K |
Total Non-Current Assets | 18.1M | 24.5M | 28.2M | 21.1M | 5.4M |
Total Assets | 392.3M | 332.7M | 382.5M | 329.5M | 187.1M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 12.3M | 4.9M | 4.8M | 5.7M | 4.9M |
Short-term Debt | - | 770.0K | 684.0K | 606.0K | 535.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 42.1M | 5.4M | 2.4M | 800.0K | 180.0K |
Total Current Liabilities | 115.5M | 55.2M | 39.8M | 43.4M | 18.0M |
Non-Current Liabilities | |||||
Long-term Debt | 3.9M | 490.0K | 1.3M | 1.9M | 2.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 112.2M | 107.8M | 78.4M | 1.9M | 2.6M |
Total Liabilities | 227.7M | 163.0M | 118.2M | 45.4M | 20.5M |
Equity | |||||
Common Stock | 61.0K | 59.0K | 56.0K | 50.0K | 44.0K |
Retained Earnings | -1.2B | -894.7M | -710.1M | -528.9M | -459.3M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 164.5M | 169.8M | 264.3M | 284.2M | 166.5M |
Key Metrics | |||||
Total Debt | 3.9M | 1.3M | 1.9M | 2.6M | 3.1M |
Working Capital | 258.7M | 253.1M | 314.4M | 265.0M | 163.7M |
Balance Sheet Composition
Rhythm Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -260.6M | -184.7M | -181.1M | -69.6M | -134.0M |
Depreciation & Amortization | 1.6M | 1.8M | 1.7M | 1.2M | 690.0K |
Stock-Based Compensation | 39.7M | 32.6M | 19.8M | 20.8M | 17.5M |
Working Capital Changes | 16.1M | 1.9M | -17.9M | 5.2M | -6.4M |
Operating Cash Flow | -89.9M | -129.0M | -172.4M | -42.7M | -122.5M |
Investing Activities | |||||
Capital Expenditures | 0 | -47.0K | -281.0K | -434.0K | -214.0K |
Acquisitions | - | 0 | 0 | 100.0M | 0 |
Investment Purchases | -268.3M | -354.9M | -251.9M | -525.0M | -86.9M |
Investment Sales | 260.6M | 355.0M | 284.2M | 361.2M | 245.6M |
Investing Cash Flow | -48.2M | -5.7M | 32.0M | -64.2M | 158.5M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 174.0M | 65.8M | 203.4M | 161.7M | 0 |
Free Cash Flow | -113.9M | -136.2M | -177.7M | -151.4M | -122.2M |
Net Change in Cash | 36.0M | -68.8M | 63.1M | 54.9M | 36.0M |
Cash Flow Trend
Rhythm Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-22.82
Forward P/E
-37.09
Price to Book
47.21
Price to Sales
42.08
PEG Ratio
-0.63
Profitability Ratios
Profit Margin
-117.16%
Operating Margin
-93.39%
Return on Equity
-116.97%
Return on Assets
-29.39%
Financial Health
Current Ratio
2.79
Debt to Equity
85.33
Beta
2.12
Per Share Data
EPS (TTM)
$-3.01
Book Value per Share
$-0.19
Revenue per Share
$2.51
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
rytm | 6.6B | -22.82 | 47.21 | -116.97% | -117.16% | 85.33 |
Vertex | 103.4B | 28.68 | 6.02 | 22.77% | 31.86% | 8.89 |
Regeneron | 63.8B | 15.13 | 2.09 | 15.34% | 31.37% | 9.04 |
Madrigal | 9.9B | -20.23 | 14.14 | -36.30% | -54.68% | 17.81 |
Bio-Techne | 9.8B | 136.85 | 5.08 | 3.68% | 6.02% | 23.14 |
Corcept Therapeutics | 9.3B | 78.71 | 14.60 | 21.70% | 18.67% | 1.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.